8-K: Moleculin Biotech Doses First Patient in Phase 3 MIRACLE Trial for R/R AML

Moleculin Biotech has initiated its Phase 3 pivotal MIRACLE trial, dosing the first patient to evaluate Annamycin in combination with Cytarabine for relapsed or refractory acute myeloid leukemia (R/R AML).

Summary

• Moleculin Biotech has dosed the first patient in its Phase 3 MIRACLE trial.
• The trial is evaluating Annamycin in combination with Cytarabine (AnnAraC) for the treatment of R/R AML.
• The MIRACLE trial is a global approval trial with sites in the US, Europe, and the Middle East.
• The company expects to unblind preliminary data from the first 45 subjects in the second half of 2025.
• The MIRACLE study is a Phase 2B/3 clinical trial whereby data from the 2B portion will be combined with the Phase 3 portion for purposes of measuring its primary endpoint.
• Part A of the trial will randomize 75 to 90 subjects to receive HiDAC combined with either placebo, 190 mg/m2 of Annamycin, or 230 mg/m2 of Annamycin.
• Part B of the trial will randomize approximately 220 additional subjects to receive either HiDAC plus placebo or HiDAC plus the optimum dose of Annamycin.
• Annamycin has Fast Track Status and Orphan Drug Designation from the FDA and EMA for the treatment of relapsed or refractory AML.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive due to the advancement of the Phase 3 trial, but tempered by the need for additional financing and the inherent risks associated with clinical trials.

Positives

• The initiation of the Phase 3 MIRACLE trial is a significant milestone for Moleculin Biotech.
• The trial has a global reach, increasing the potential patient pool.
• The adaptive design of the trial allows for dose optimization based on early data.
• Annamycin has already received Fast Track Status and Orphan Drug Designation, potentially expediting the approval process.
• The company expects to unblind preliminary data from the first 45 subjects in the second half of 2025.

Risks

• The company will require significant additional financing to conduct its clinical trials.
• The forward-looking statements are subject to risks and uncertainties, including those discussed in the company's SEC filings.
• The study is subject to appropriate future filings with potential additional feedback from the FDA and their foreign equivalents.

Future Outlook

The company expects to unblind preliminary data from the first 45 subjects in the second half of 2025 and the second unblinding in the first half of 2026. The company believes it has substantially de-risked the development pathway towards a potential approval for Annamycin for the treatment of AML.

Management Comments

• Walter Klemp, Chairman and Chief Executive Officer of Moleculin, commented that the start of patient dosing represents a huge milestone for Moleculin and the AML community.
• Klemp stated that the team remains focused on bringing clinical sites online and enrolling patients.

Industry Context

This announcement is relevant to the pharmaceutical industry, specifically in the area of oncology and drug development for AML. It positions Moleculin Biotech as a key player in developing new treatments for relapsed or refractory AML.

Comparison to Industry Standards

• Several companies are developing therapies for R/R AML, including Agios Pharmaceuticals with Tibsovo and Servier Pharmaceuticals with Asparlas.
• The MIRACLE trial's adaptive design is becoming increasingly common in clinical trials to optimize treatment regimens based on early data.
• The use of Fast Track and Orphan Drug Designations is a standard strategy to expedite the development and approval of drugs for rare diseases.

Stakeholder Impact

• Positive impact on AML patients and the medical community by potentially providing a new treatment option.
• Potential positive impact on shareholders if the trial is successful and the drug is approved.
• Impact on employees through continued employment and potential growth of the company.

Next Steps

• Bring clinical sites online in the U.S., Europe and Middle East.
• Enroll patients in the MIRACLE trial.
• Reach the first unblinding (45 subjects) in the second half of 2025.
• Reach the second unblinding in the first half of 2026.
• File appropriate documentation with the FDA and foreign equivalents.

Key Dates

Keywords

Annamycin, MIRACLE Trial, R/R AML, Moleculin Biotech, Phase 3 Trial, Cytarabine, Oncology, Clinical Trial